Journal Browser

► Journal Browser

Efficacy, Safety, and Immunogenicity of Vaccines against Viruses: From Network Medicine to Clinical Experimentation 2nd Edition

Share This Special Issue

Special Issue Information

Dear Colleagues,

Despite the availability of effective vaccines against many diseases (e.g., COVID-19, Influenza, Varicella Virus, HPV), there is a need to study both novel and the existing vaccines and create prioritization campaigns to maintain vaccine-induced protection against variant strains and breakthrough infections.

Bioinformatics and network medicine help the research community to investigate the efficacy, safety and immunogenicity of vaccines and the mutual relationships among them.

An increasing body of evidence confirms that the synergistic integration of network medicine and clinical experimentation may improve the quality of existing vaccines as well as the development of novel ones. This Special Issue aims to foster discussion on following topics:

Development of novel vaccines;
Study of the immunogenicity of existing vaccines;
Age- and sex-based differences;
Introduction of novel prioritisation methods.

Dr. Pietro Hiram Guzzi
Dr. Jayanta Kumar Das
Dr. Marianna Milano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

vaccines
vaccine security
computational bioinformatics
network analysis
data science

Published Papers (2 papers)

Download All Papers

Review

Jump to: Other

11 pages, 250 KiB

Open AccessReview

Evaluation of Vaccine Immunogenicity—Correlates to Real-World Protection: Influenza

by Csaba Laszlofy, Gyorgy Fazekas, Zoltan Barath and Zoltan Vajo

Viruses 2024, 16(3), 441; https://doi.org/10.3390/v16030441 - 12 Mar 2024

Viewed by 975

Abstract

Recent events highlighted that, despite decades of studying vaccine immunogenicity and efforts toward finding correlates of protection, evaluating real-world vaccine efficacy as well as establishing meaningful licensing criteria still represents a significant challenge. In this paper, we review all aspects of influenza vaccine immunogenicity, including animal and human challenge studies, humoral and cellular immunity parameters, and their potential correlation with real-life protection from disease. Full article

(This article belongs to the Special Issue Efficacy, Safety, and Immunogenicity of Vaccines against Viruses: From Network Medicine to Clinical Experimentation 2nd Edition)

Other

Jump to: Review

10 pages, 1924 KiB

Open AccessBrief Report

Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1

by Muhammad Saqib Sohail, Syed Faraz Ahmed, Ahmed Abdul Quadeer and Matthew R. McKay

Viruses 2024, 16(3), 473; https://doi.org/10.3390/v16030473 - 20 Mar 2024

Viewed by 939

Abstract

The SARS-CoV-2 Omicron sub-variants BA.2.86 and JN.1 contain multiple mutations in the spike protein that were not present in previous variants of concern and Omicron sub-variants. Preliminary research suggests that these variants reduce the neutralizing capability of antibodies induced by vaccines, which is particularly significant for JN.1. This raises concern as many widely deployed COVID-19 vaccines are based on the spike protein of the ancestral Wuhan strain of SARS-CoV-2. While T cell responses have been shown to be robust against previous SARS-CoV-2 variants, less is known about the impact of mutations in BA.2.86 and JN.1 on T cell responses. We evaluate the effect of mutations specific to BA.2.86 and JN.1 on experimentally determined T cell epitopes derived from the spike protein of the ancestral Wuhan strain and the spike protein of the XBB.1.5 strain that has been recommended as a booster vaccine. Our data suggest that BA.2.86 and JN.1 affect numerous T cell epitopes in spike compared to previous variants; however, the widespread loss of T cell recognition against these variants is unlikely. Full article

(This article belongs to the Special Issue Efficacy, Safety, and Immunogenicity of Vaccines against Viruses: From Network Medicine to Clinical Experimentation 2nd Edition)

► Show Figures